TERM CREDIT AGREEMENT dated as of December 19, 2014 among MYLAN INC., as a Borrower and The other Borrowers and Guarantors party hereto and BANK OF AMERICA, N.A., as Administrative Agent and the Lenders party heretoTerm Credit Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations • New York
This TERM CREDIT AGREEMENT (this “Agreement”) is dated as of December 19, 2014 among MYLAN INC., a Pennsylvania corporation (“Mylan”), certain Affiliates and Subsidiaries of Mylan from time to time party hereto as a Designated Borrower, Successor Borrower or Guarantor, each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT Dated as of January 27, 2015 among MYLAN PHARMACEUTICALS INC., individually and as Servicer, MYLAN SECURITIZATION LLC, as Seller, THE CONDUIT PURCHASERS FROM TIME TO TIME PARTY HERETO, THE COMMITTED...Receivables Purchase Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT dated as of January 27, 2015 (this “Agreement”), among Mylan Pharmaceuticals Inc., a West Virginia corporation (“MPI”), individually and as initial Servicer, Mylan Securitization LLC, a Delaware limited liability company, as seller (“Seller”), Victory Receivables Corporation, a Delaware corporation (“Victory”), as a conduit purchaser and the other conduit purchasers from time to time party hereto (each individually, a “Conduit Purchaser” and collectively with Victory, “Conduit Purchasers”), PNC Bank, National Association, a national banking association (“PNC”), as a committed purchaser, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, a Japanese banking corporation acting through its New York Branch (“BTMUNY”), as a committed purchaser and the other committed purchasers from time to time party hereto (each individually, a “Committed Purchaser” and collectively with PNC and BTMUNY, “Committed Purchasers” and collectively w
AMENDED AND RESTATED PURCHASE AND CONTRIBUTION AGREEMENT dated as of January 27, 2015 between MYLAN PHARMACEUTICALS INC., as Originator and as Servicer, and MYLAN SECURITIZATION LLC, as BuyerPurchase and Contribution Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED PURCHASE AND CONTRIBUTION AGREEMENT dated as of January 27, 2015 (this “Agreement”) is between MYLAN PHARMACEUTICALS INC., a West Virginia corporation (“MPI”), as originator and seller (“Originator”), and as initial servicer (in such capacity, the “Servicer”), and Mylan Securitization LLC, a Delaware limited liability company (the “Buyer”). For good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
REVOLVING CREDIT AGREEMENT dated as of December 19, 2014 among MYLAN INC., as a Borrower and The other Borrowers and Guarantors party hereto and BANK OF AMERICA, N.A., as Administrative Agent and the Lenders and the Issuing Banks party heretoRevolving Credit Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations • New York
This REVOLVING CREDIT AGREEMENT (this “Agreement”) is dated as of December 19, 2014 among MYLAN INC., a Pennsylvania corporation (“Mylan”), certain Affiliates and Subsidiaries of Mylan from time to time party hereto as a Designated Borrower, Successor Borrower or Guarantor, each Lender and Issuing Bank from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
Letter AgreementLetter Agreement • March 2nd, 2015 • Mylan Inc. • Pharmaceutical preparations
Reference is made to your Third Amended and Restated Executive Employment Agreement, entered into on February 25, 2014 and effective as of January 1, 2014, with Mylan Inc. (the “Company”), as such agreement may be amended from time to time (the “Employment Agreement”). The Employment Agreement provides for certain benefits upon a termination of employment with Good Reason (as such term is defined in the Employment Agreement). By executing this letter agreement, for good and valuable consideration (including the agreement of the parties hereto that, by entering into this letter agreement, immediately following the consummation of the Transaction (as defined below), you shall have the title and position of Executive Chairman of Mylan N.V., the term “Executive Chairman” as used in the Employment Agreement shall include the title and position of Executive Chairman of Mylan N.V., the authority, duties and responsibilities set forth in Section 1 of the Employment Agreement shall include the
Transition and Succession Agreement Waiver LetterMylan Inc. • March 2nd, 2015 • Pharmaceutical preparations
Reference is made to your Transition and Succession Agreement with Mylan Inc. (the “Company”), as such agreement has been and may be amended from time to time (the “T&S Agreement”). The T&S Agreement provides for the possibility of enhanced benefits or rights following a Change in Control of the Company (as such term is defined in the T&S Agreement). By executing this waiver letter, for good and valuable consideration (including your continued employment and continued participation in the Company’s incentive plans and programs), you acknowledge and agree that the transactions consummated pursuant to the Business Transfer Agreement and Plan of Merger, dated as of July 13, 2014, by and among Abbott Laboratories, an Illinois corporation, the Company and the other parties thereto, as such agreement may be amended from time to time, shall not constitute a Change in Control for any purpose of the T&S Agreement. All other provisions of the T&S Agreement, as modified by the foregoing, shall re
Retirement Benefit Agreement Waiver LetterMylan Inc. • March 2nd, 2015 • Pharmaceutical preparations
Reference is made to your Retirement Benefit Agreement with Mylan Inc. (the “Company”), as such agreement has been and may be amended from time to time (the “RBA”). The RBA provides for the possibility of accelerated vesting and certain other modifications upon a Change in Control of the Company (as such term is defined in the RBA). By executing this waiver letter, for good and valuable consideration (including your continued employment and continued participation in the Company’s incentive plans and programs), you acknowledge and agree that the transactions consummated pursuant to the Business Transfer Agreement and Plan of Merger, dated as of July 13, 2014, by and among Abbott Laboratories, an Illinois corporation, the Company and the other parties thereto, as such agreement may be amended from time to time, shall not constitute a Change in Control for any purpose of the RBA. All other provisions of the RBA, as modified by the foregoing, shall remain in full force and effect notwiths
